Efaproxiral: A Radiation Enhancer Used in Brain Metastases from Breast Cancer

Abstract

Spanish

French

OBJECTIVE

To review the mechanism of action and clinical data of efaproxiral use in brain metastases of breast cancer.

DATA SOURCES

Articles were identified through MEDLINE (1966–June 2005) and EMBASE (1980–May 2005) searches using the key words efaproxiral and RSR13. Published abstracts over the previous 10 years from various scientific meetings, including American Society of Clinical Oncology and San Antonio Breast Cancer Symposium, were also searched for investigations of efaproxiral. Data on efaproxiral were also provided by Allos Therapeutics.

STUDY SELECTION AND DATA EXTRACTION

All published clinical data in humans regarding efaproxiral use in brain metastases from breast cancer were selected for this review. In addition, published studies in humans that discussed the pharmacokinetics, pharmacodynamics, and safety of efaproxiral were evaluated.

DATA SYNTHESIS

Efaproxiral is a synthetic allosteric modifier of hemoglobin that results in a shift of the hemoglobin oxygen dissociation curve to the right. Therefore, oxygen is more readily released from hemoglobin into tissues. Efaproxiral demonstrated a significant survival benefit when used as a radiation enhancer in patients with brain metastases originating from breast cancer. The safety profile of efaproxiral and improved survival rates make this agent advantageous over radiation alone. Further investigation and results from the ongoing clinical trials will help to define the role of efaproxiral in clinical practice.

CONCLUSIONS

Efaproxiral is the first synthetic allosteric modifier to demonstrate significant improvement in survival in patients undergoing radiation therapy for brain metastases of breast cancer. Validation of this effect in ongoing clinical trials will be important in determining the role of efaproxiral in brain metastases from breast cancer.

Keywords

brain metastases breast cancer efaproxiral

Get full access to this article

View all access options for this article.

References

1. Lin

Bellon

Winer

EP.

CNS metastases in breast cancer. J Clin Oncol 2004;22:3608–17.

2. Nordsmark

Overgaard

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.

3. Suh

Stea

Kresl

Nabid

Fortin

Mercer

Results from a subgroup analysis of patients with metastatic breast cancer (MBC) in a phase 3, randomized, open-label, comparative study of standard whole brain radiation therapy (WBRT) with supplemental oxygen, with or without RSR13, in patients with brain metastases (abstract). Presented at: San Antonio Breast Conference, December 2003.

4. The ENRICH trial: a phase 3 randomized, open-label comparative study of standard whole brain radiation therapy with supplemental oxygen, with or without concurrent Efaproxyn (efaproxiral), in women with brain metastases from breast cancer. www.allos.com/index.cfm?p2=50290146&category1=clin&category2=enri&category3=x&category4=x&category5=x&category6=x (accessed 2005 Jan 17).

5. Brizel

Sibley

Prosnitz

Scher

Dewhirst

MW.

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285–9.

6. Stadler

Becker

Feldmann

Hansgen

Dunst

Wurschmidt

Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749–54.

7. Fyles

Milosevic

Wong

Kavanagh

Pintilie

Sun

Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149–56.

8. Winslow

Vandegriff

KD.

Oxygen–hemoglobin dissociation curve. In: Crystal

West

Weibel

Barnes

, eds. The lung: scientific foundations. 2nd ed. Philadelphia: Lippincott–Raven, 1997:1626–32.

9. Hemoglobin. From Wikipedia, the free encyclopedia. http://en.wikipedia.org/wiki/Hemoglobin (accessed 2005 Mar 3).

10.

10. Kavanagh

Khandelwal

Schmidt-Ullrich

Roberts

Shaw

Pearlman

A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 2001;41:1133–9.

11.

11. Wahr

Gerber

Jürgen

Baliga

Allosteric modification of oxygen delivery by hemoglobin. Anesth Analg 2001;92:615–20.

12.

12. Abraham

Wireko

Randad

Poyard

Kister

Rohn

Allosteric modifiers of Hb:2-[4[[3,5disubstituted aniline)carbonyl] methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of Hb in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 1992;31:9141–9.

13.

13. Teicher

Ara

Emi

Kakeji

Ikebe

Maehara

RSR13: effects on tumor oxygenation and response to therapy. Drug Dev Res 1996;38:1–11.

14.

14. Kavanagh

Secomb

Hsu

Peck-Sun

Venitz

Dewhirst

MW.

A theoretical model for the effects of reduced hemoglobin–oxygen affinity on tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:172–9.

15.

15. Safo

Moure

Burnett

Joshi

Abraham

DJ.

High resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci 2001;10:951–7.

16.

16. Grinberg

Miyake

Hou

Steffen

Swartz

HM.

The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Adv Exp Med Biol 2003;530:287–96.

17.

17. Rockwell

Kelley

RSR13, a synthetic allosteric modifer of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat Oncol Invest 1998;6:199–208.

18.

18. Kleinberg

Grossman

Piantadosi

Pearlman

Engelhard

Lesser

Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 1999;17:2593–603.

19.

19. Suh

JH.

Efaproxiral: a novel radiation sensitizer. Expert Opin Investig Drugs 2004;13:543–50.

20.

20. Hermening

Venitz

Development and validation of a HPLC assay for RSR13 and its acyl glucuronide in preclinical and clinical biological samples (abstract). Presented at: Tenth International Symposium on Pharmaceutical and Biomedical Analysis, Washington, DC, May 12, 1999.

21.

21. Hermening

Venitz

In vitro glucuronidation of RSR13: prediction of in-vitro and in-vivo intrinsic hepatic clearances and metabolic interaction with probenecid (abstract). 101st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 15–17, 2000. Clin Pharmacol Ther 2000;67:133.

22.

22. Hermening

Venitz

In-vitro pharmacokinetics of the allosteric hemoglobin (HB) modifier RSR13, and its acyl glucuronide (RSR13AG). Presented at: 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November 14–18, 1999.

23.

23. Shaw

Scott

Suh

Kadish

Baldassare

Hackman

RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. J Clin Oncol 2003;21:2364–71.

24.

24. Gaspar

Scott

Rotman

Asbell

Phillips

Wasserman

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.

25.

25. Gaspar

Scott

Murray

Curran

Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001–6.

26.

26. Suh

Stea

Kresl

Nabid

Fortin

Mercier

RT-13. A phase 3, randomized, open-label, comparative study of standard whole brain radiation therapy (WBRT) with supplemental oxygen (O₂), with or without RSR13, in patients with brain metastases. Presented at: Eighth Annual Scientific Meeting of the Society of Neuro-Oncology. Keystone, CO, November 13–16, 2003.

27.

27. Suh

Stea

Nabid

Kresl

Fortin

Mercier

J P

Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O₂), with or without RSR13 (efaproxiral) in patients with brain metastases: results of the randomized REACH (RT-009) study (abstract 1534). J Clin Oncol 2004;22:14S.

28.

28. Shaw

Stea

Pinter

Hammoud

Cagnoni

Hackman

Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009) (abstract 1561). J Clin Oncol 2004;22:14S.

29.

29. Burke

Malhotra

Shapiro

JI.

Effects of enhanced oxygenation release from hemoglobin by RSR13 in an acute renal failure model. Kidney Int 2001;60:1407–14.

30.

30. Stea

Nabid

Kresl

Roa

Mechtler

Senzer

Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy (abstract 3040). J Clin Oncol 2004;22:14S.